酪氨酸激酶抑制剂和铂基化疗对不可切除或转移性肝胆管癌患者的全身治疗

IF 11.6 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
Liver Cancer Pub Date : 2022-06-14 eCollection Date: 2022-09-01 DOI:10.1159/000525488
Elia Gigante, Christian Hobeika, Brigitte Le Bail, Valérie Paradis, David Tougeron, Marie Lequoy, Mohamed Bouattour, Jean-Frederic Blanc, Nathalie Ganne-Carrié, Henri Tran, Clémence Hollande, Manon Allaire, Giuliana Amaddeo, Hélène Regnault, Paul Vigneron, Maxime Ronot, Laure Elkrief, Gontran Verset, Eric Trepo, Aziz Zaanan, Marianne Ziol, Massih Ningarhari, Julien Calderaro, Julien Edeline, Jean-Charles Nault
{"title":"酪氨酸激酶抑制剂和铂基化疗对不可切除或转移性肝胆管癌患者的全身治疗","authors":"Elia Gigante,&nbsp;Christian Hobeika,&nbsp;Brigitte Le Bail,&nbsp;Valérie Paradis,&nbsp;David Tougeron,&nbsp;Marie Lequoy,&nbsp;Mohamed Bouattour,&nbsp;Jean-Frederic Blanc,&nbsp;Nathalie Ganne-Carrié,&nbsp;Henri Tran,&nbsp;Clémence Hollande,&nbsp;Manon Allaire,&nbsp;Giuliana Amaddeo,&nbsp;Hélène Regnault,&nbsp;Paul Vigneron,&nbsp;Maxime Ronot,&nbsp;Laure Elkrief,&nbsp;Gontran Verset,&nbsp;Eric Trepo,&nbsp;Aziz Zaanan,&nbsp;Marianne Ziol,&nbsp;Massih Ningarhari,&nbsp;Julien Calderaro,&nbsp;Julien Edeline,&nbsp;Jean-Charles Nault","doi":"10.1159/000525488","DOIUrl":null,"url":null,"abstract":"<p><strong>Backgrounds and aims: </strong>Even if no systemic treatment is currently validated for unresectable hepatocellular-cholangiocarcinoma (cHCC-CCA), tyrosine kinase inhibitors (TKIs) and platinum-based chemotherapy are frequently used in clinical practice. Our study aims to describe the effectiveness of first-line systemic treatments in patients with cHCC-CCA.</p><p><strong>Patients and methods: </strong>Patients with histological diagnosis of unresectable or metastatic cHCC-CCA confirmed by a centralized review (WHO classification 2019) and who received systemic treatment from 2009 to 2020 were included retrospectively in 11 centers. The outcomes of patients with cHCC-CCA were compared with patients with hepatocellular carcinoma (HCC) treated by sorafenib (<i>n</i> = 117) and with intrahepatic cholangiocarcinoma (iCCA, <i>n</i> = 94) treated mainly by platinum-based chemotherapy using a frailty Cox model. The efficacy of TKIs and platinum-based chemotherapies in patients with cHCC-CCA was assessed using a doubly robust estimator.</p><p><strong>Results: </strong>A total of 83 patients with cHCC-CCA were included and were predominantly male (72%) with underlying cirrhosis (55%). 67% of patients had extrahepatic metastases and 31% macrovascular tumor invasion. cHCC-CCAs were more often developed on cirrhosis (55.4%) than iCCA (26.6%) but less frequently than HCC (80.2%) (<i>p</i> < 0.001). Both HCC (36.8% and cHCC-CCA (66.2%) had less frequent extrahepatic metastases than iCCA (81%) (<i>p</i> < 0.001). Unadjusted overall survival (OS) was better in iCCA (13 months) compared to cHCC-CCA (12 months) and HCC (11 months) (<i>p</i> = 0.130). In multivariable analysis, after adjustment by a Cox frailty model, patients with cHCC-CCA had the same survival as HCC and iCCA (HR = 0.67, 95% CI: 0.37-1.22, <i>p</i> = 0.189 and HR = 0.66, 95% CI: 0.43-1.02, <i>p</i> = 0.064, respectively). ALBI score (HR = 2.15; 95% CI: 1.23-3.76; <i>p</i> = 0.009), ascites (HR = 3.45, 95% CI: 1.31-9.03, <i>p</i> = 0.013), and tobacco use (HR = 2.29, 95% CI: 1.08-4.87, <i>p</i> = 0.032) were independently associated with OS in patients with cHCC-CCA. Among patients with cHCC-CCA, 25 patients treated with TKI were compared with 54 patients who received platinum-based chemotherapies. Patients treated with TKI had a median OS of 8.3 months compared to 11.9 months for patients treated with platinum-based chemotherapy (<i>p</i> = 0.86). After a robust doubly adjustment on tumor number and size, vascular invasion, ALBI, MELD, and cirrhosis, the type of treatment did not impact OS (HR = 0.92, 95% CI: 0.27-3.15, <i>p</i> = 0.88) or progression-free survival (HR = 1.24, 95% CI: 0.44-3.49, <i>p</i> = 0.67).</p><p><strong>Conclusions: </strong>First-line systemic treatments with TKIs or platinum-based chemotherapies have similar efficacy in patients with unresectable/metastatic cHCC-CCA. The ALBI score predicts OS.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"11 5","pages":"460-473"},"PeriodicalIF":11.6000,"publicationDate":"2022-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ac/9b/lic-0011-0460.PMC9485952.pdf","citationCount":"6","resultStr":"{\"title\":\"Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma.\",\"authors\":\"Elia Gigante,&nbsp;Christian Hobeika,&nbsp;Brigitte Le Bail,&nbsp;Valérie Paradis,&nbsp;David Tougeron,&nbsp;Marie Lequoy,&nbsp;Mohamed Bouattour,&nbsp;Jean-Frederic Blanc,&nbsp;Nathalie Ganne-Carrié,&nbsp;Henri Tran,&nbsp;Clémence Hollande,&nbsp;Manon Allaire,&nbsp;Giuliana Amaddeo,&nbsp;Hélène Regnault,&nbsp;Paul Vigneron,&nbsp;Maxime Ronot,&nbsp;Laure Elkrief,&nbsp;Gontran Verset,&nbsp;Eric Trepo,&nbsp;Aziz Zaanan,&nbsp;Marianne Ziol,&nbsp;Massih Ningarhari,&nbsp;Julien Calderaro,&nbsp;Julien Edeline,&nbsp;Jean-Charles Nault\",\"doi\":\"10.1159/000525488\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Backgrounds and aims: </strong>Even if no systemic treatment is currently validated for unresectable hepatocellular-cholangiocarcinoma (cHCC-CCA), tyrosine kinase inhibitors (TKIs) and platinum-based chemotherapy are frequently used in clinical practice. Our study aims to describe the effectiveness of first-line systemic treatments in patients with cHCC-CCA.</p><p><strong>Patients and methods: </strong>Patients with histological diagnosis of unresectable or metastatic cHCC-CCA confirmed by a centralized review (WHO classification 2019) and who received systemic treatment from 2009 to 2020 were included retrospectively in 11 centers. The outcomes of patients with cHCC-CCA were compared with patients with hepatocellular carcinoma (HCC) treated by sorafenib (<i>n</i> = 117) and with intrahepatic cholangiocarcinoma (iCCA, <i>n</i> = 94) treated mainly by platinum-based chemotherapy using a frailty Cox model. The efficacy of TKIs and platinum-based chemotherapies in patients with cHCC-CCA was assessed using a doubly robust estimator.</p><p><strong>Results: </strong>A total of 83 patients with cHCC-CCA were included and were predominantly male (72%) with underlying cirrhosis (55%). 67% of patients had extrahepatic metastases and 31% macrovascular tumor invasion. cHCC-CCAs were more often developed on cirrhosis (55.4%) than iCCA (26.6%) but less frequently than HCC (80.2%) (<i>p</i> < 0.001). Both HCC (36.8% and cHCC-CCA (66.2%) had less frequent extrahepatic metastases than iCCA (81%) (<i>p</i> < 0.001). Unadjusted overall survival (OS) was better in iCCA (13 months) compared to cHCC-CCA (12 months) and HCC (11 months) (<i>p</i> = 0.130). In multivariable analysis, after adjustment by a Cox frailty model, patients with cHCC-CCA had the same survival as HCC and iCCA (HR = 0.67, 95% CI: 0.37-1.22, <i>p</i> = 0.189 and HR = 0.66, 95% CI: 0.43-1.02, <i>p</i> = 0.064, respectively). ALBI score (HR = 2.15; 95% CI: 1.23-3.76; <i>p</i> = 0.009), ascites (HR = 3.45, 95% CI: 1.31-9.03, <i>p</i> = 0.013), and tobacco use (HR = 2.29, 95% CI: 1.08-4.87, <i>p</i> = 0.032) were independently associated with OS in patients with cHCC-CCA. Among patients with cHCC-CCA, 25 patients treated with TKI were compared with 54 patients who received platinum-based chemotherapies. Patients treated with TKI had a median OS of 8.3 months compared to 11.9 months for patients treated with platinum-based chemotherapy (<i>p</i> = 0.86). After a robust doubly adjustment on tumor number and size, vascular invasion, ALBI, MELD, and cirrhosis, the type of treatment did not impact OS (HR = 0.92, 95% CI: 0.27-3.15, <i>p</i> = 0.88) or progression-free survival (HR = 1.24, 95% CI: 0.44-3.49, <i>p</i> = 0.67).</p><p><strong>Conclusions: </strong>First-line systemic treatments with TKIs or platinum-based chemotherapies have similar efficacy in patients with unresectable/metastatic cHCC-CCA. The ALBI score predicts OS.</p>\",\"PeriodicalId\":18156,\"journal\":{\"name\":\"Liver Cancer\",\"volume\":\"11 5\",\"pages\":\"460-473\"},\"PeriodicalIF\":11.6000,\"publicationDate\":\"2022-06-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ac/9b/lic-0011-0460.PMC9485952.pdf\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Liver Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000525488\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/9/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000525488","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/9/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 6

摘要

背景和目的:即使目前没有针对不可切除的肝细胞胆管癌(cHCC-CCA)的全身治疗,酪氨酸激酶抑制剂(TKIs)和铂基化疗在临床实践中经常使用。我们的研究旨在描述一线全身治疗对cHCC-CCA患者的有效性。患者和方法:回顾性纳入2009年至2020年接受全身治疗的11个中心的组织学诊断为不可切除或转移性cHCC-CCA (WHO分类2019)的患者。采用脆性Cox模型,将cHCC-CCA患者的预后与接受索拉非尼治疗的肝细胞癌(HCC)患者(n = 117)和主要接受铂类化疗的肝内胆管癌(iCCA, n = 94)患者进行比较。TKIs和铂类化疗对cHCC-CCA患者的疗效采用双稳健估计器进行评估。结果:共纳入83例cHCC-CCA患者,主要为男性(72%),伴有肝硬化(55%)。67%的患者有肝外转移,31%的患者有大血管肿瘤浸润。chcc - cca发生于肝硬化的发生率(55.4%)高于iCCA(26.6%),但低于HCC (80.2%) (p < 0.001)。HCC(36.8%)和cHCC-CCA(66.2%)的肝外转移发生率均低于iCCA (81%) (p < 0.001)。与cHCC-CCA(12个月)和HCC(11个月)相比,iCCA的未调整总生存期(OS)(13个月)更好(p = 0.130)。在多变量分析中,经Cox脆弱性模型调整后,cHCC-CCA患者与HCC和iCCA患者的生存期相同(HR = 0.67, 95% CI: 0.37-1.22, p = 0.189; HR = 0.66, 95% CI: 0.43-1.02, p = 0.064)。ALBI评分(HR = 2.15;95% ci: 1.23-3.76;p = 0.009)、腹水(HR = 3.45, 95% CI: 1.31-9.03, p = 0.013)和吸烟(HR = 2.29, 95% CI: 1.08-4.87, p = 0.032)与cHCC-CCA患者的OS独立相关。在cHCC-CCA患者中,25例患者接受TKI治疗,54例患者接受铂类化疗。接受TKI治疗的患者中位OS为8.3个月,而接受铂类化疗的患者中位OS为11.9个月(p = 0.86)。在对肿瘤数量和大小、血管侵犯、ALBI、MELD和肝硬化进行了强有力的双重调整后,治疗类型没有影响OS (HR = 0.92, 95% CI: 0.27-3.15, p = 0.88)或无进展生存期(HR = 1.24, 95% CI: 0.44-3.49, p = 0.67)。结论:一线全身治疗TKIs或铂基化疗对不可切除/转移性cHCC-CCA患者的疗效相似。ALBI评分预测OS。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma.

Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma.

Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma.

Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma.

Backgrounds and aims: Even if no systemic treatment is currently validated for unresectable hepatocellular-cholangiocarcinoma (cHCC-CCA), tyrosine kinase inhibitors (TKIs) and platinum-based chemotherapy are frequently used in clinical practice. Our study aims to describe the effectiveness of first-line systemic treatments in patients with cHCC-CCA.

Patients and methods: Patients with histological diagnosis of unresectable or metastatic cHCC-CCA confirmed by a centralized review (WHO classification 2019) and who received systemic treatment from 2009 to 2020 were included retrospectively in 11 centers. The outcomes of patients with cHCC-CCA were compared with patients with hepatocellular carcinoma (HCC) treated by sorafenib (n = 117) and with intrahepatic cholangiocarcinoma (iCCA, n = 94) treated mainly by platinum-based chemotherapy using a frailty Cox model. The efficacy of TKIs and platinum-based chemotherapies in patients with cHCC-CCA was assessed using a doubly robust estimator.

Results: A total of 83 patients with cHCC-CCA were included and were predominantly male (72%) with underlying cirrhosis (55%). 67% of patients had extrahepatic metastases and 31% macrovascular tumor invasion. cHCC-CCAs were more often developed on cirrhosis (55.4%) than iCCA (26.6%) but less frequently than HCC (80.2%) (p < 0.001). Both HCC (36.8% and cHCC-CCA (66.2%) had less frequent extrahepatic metastases than iCCA (81%) (p < 0.001). Unadjusted overall survival (OS) was better in iCCA (13 months) compared to cHCC-CCA (12 months) and HCC (11 months) (p = 0.130). In multivariable analysis, after adjustment by a Cox frailty model, patients with cHCC-CCA had the same survival as HCC and iCCA (HR = 0.67, 95% CI: 0.37-1.22, p = 0.189 and HR = 0.66, 95% CI: 0.43-1.02, p = 0.064, respectively). ALBI score (HR = 2.15; 95% CI: 1.23-3.76; p = 0.009), ascites (HR = 3.45, 95% CI: 1.31-9.03, p = 0.013), and tobacco use (HR = 2.29, 95% CI: 1.08-4.87, p = 0.032) were independently associated with OS in patients with cHCC-CCA. Among patients with cHCC-CCA, 25 patients treated with TKI were compared with 54 patients who received platinum-based chemotherapies. Patients treated with TKI had a median OS of 8.3 months compared to 11.9 months for patients treated with platinum-based chemotherapy (p = 0.86). After a robust doubly adjustment on tumor number and size, vascular invasion, ALBI, MELD, and cirrhosis, the type of treatment did not impact OS (HR = 0.92, 95% CI: 0.27-3.15, p = 0.88) or progression-free survival (HR = 1.24, 95% CI: 0.44-3.49, p = 0.67).

Conclusions: First-line systemic treatments with TKIs or platinum-based chemotherapies have similar efficacy in patients with unresectable/metastatic cHCC-CCA. The ALBI score predicts OS.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Liver Cancer
Liver Cancer Medicine-Oncology
CiteScore
20.80
自引率
7.20%
发文量
53
审稿时长
16 weeks
期刊介绍: Liver Cancer is a journal that serves the international community of researchers and clinicians by providing a platform for research results related to the causes, mechanisms, and therapy of liver cancer. It focuses on molecular carcinogenesis, prevention, surveillance, diagnosis, and treatment, including molecular targeted therapy. The journal publishes clinical and translational research in the field of liver cancer in both humans and experimental models. It publishes original and review articles and has an Impact Factor of 13.8. The journal is indexed and abstracted in various platforms including PubMed, PubMed Central, Web of Science, Science Citation Index, Science Citation Index Expanded, Google Scholar, DOAJ, Chemical Abstracts Service, Scopus, Embase, Pathway Studio, and WorldCat.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信